Press coverage about Heska (NASDAQ:HSKA) has been trending somewhat positive on Tuesday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Heska earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.7880657546024 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Comparing Heska (HSKA) and The Competition (americanbankingnews.com)
- Heska (HSKA) Earns Neutral Rating from B. Riley (americanbankingnews.com)
- Heska (HSKA) PT Raised to $120.00 (americanbankingnews.com)
- Heska (HSKA) Upgraded at BidaskClub (americanbankingnews.com)
- Heska: Attractive Opportunity (seekingalpha.com)
A number of brokerages recently weighed in on HSKA. B. Riley decreased their price objective on shares of Heska from $93.00 to $77.00 and set a “neutral” rating for the company in a report on Thursday, March 1st. BidaskClub upgraded shares of Heska from a “sell” rating to a “hold” rating in a report on Friday, March 16th. Canaccord Genuity restated a “buy” rating and issued a $95.00 price objective on shares of Heska in a report on Thursday, March 1st. TheStreet lowered shares of Heska from a “b-” rating to a “c+” rating in a report on Friday, March 9th. Finally, ValuEngine lowered shares of Heska from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. Heska presently has an average rating of “Hold” and a consensus target price of $104.08.
Heska (NASDAQ:HSKA) last posted its earnings results on Wednesday, February 28th. The medical research company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.07. Heska had a net margin of 7.53% and a return on equity of 16.23%. The business had revenue of $36.04 million during the quarter, compared to the consensus estimate of $40.56 million. During the same quarter in the previous year, the firm posted $0.46 EPS. The firm’s revenue was down 8.8% on a year-over-year basis. equities analysts predict that Heska will post 1.95 earnings per share for the current year.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.